T R Fritsche

Summary

Affiliation: JMI Laboratories
Country: USA

Publications

  1. ncbi request reprint Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003)
    David M Johnson
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 56:69-74. 2006
  2. pmc NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America
    Sudha Pottumarthy
    University of Washington School of Medicine, Seattle, Washington, USA
    Emerg Infect Dis 9:999-1002. 2003
  3. pmc Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    BMC Infect Dis 7:29. 2007
  4. doi request reprint Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 61:1092-8. 2008
  5. ncbi request reprint Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase
    T R Fritsche
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Clin Microbiol Infect 10:857-60. 2004
  6. pmc Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections
    Thomas R Fritsche
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:1187-9. 2008
  7. ncbi request reprint Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004)
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:19-26. 2007
  8. pmc Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance
    Thomas R Fritsche
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 49:1468-76. 2005
  9. ncbi request reprint Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:187-93. 2005
  10. ncbi request reprint Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004)
    Thomas R Fritsche
    JMI Laboratories, Inc, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:195-201. 2005

Detail Information

Publications102 found, 100 shown here

  1. ncbi request reprint Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003)
    David M Johnson
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 56:69-74. 2006
    ....
  2. pmc NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America
    Sudha Pottumarthy
    University of Washington School of Medicine, Seattle, Washington, USA
    Emerg Infect Dis 9:999-1002. 2003
    ..This first report of NmcA detected in North America warrants further investigation into its distribution and clinical impact...
  3. pmc Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)
    Helio S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    BMC Infect Dis 7:29. 2007
    ..We evaluated the in vitro activity of this compound and selected comparator agents tested against clinical strains of staphylococci and enterococci collected in European medical centers in 2005...
  4. doi request reprint Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 61:1092-8. 2008
    ..We evaluated the spectrum and potency of omiganan against pathogens commonly associated with such infections...
  5. ncbi request reprint Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase
    T R Fritsche
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Clin Microbiol Infect 10:857-60. 2004
    ..9% and 96.7% of MIC values, respectively, were within +/- 1 log(2) dilution step, thereby demonstrating a high degree of reliability of the dry-form MIC product for clinical studies...
  6. pmc Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections
    Thomas R Fritsche
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:1187-9. 2008
    ..All fungi were inhibited by omiganan at concentrations well below the 1% (10,000 microg/ml) clinical formulation, including species with reduced susceptibility to azoles and echinocandins...
  7. ncbi request reprint Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004)
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:19-26. 2007
    ..These in vitro data suggest that garenoxacin warrants further clinical studies in SSTI, especially against staphylococci and streptococcal pathogens...
  8. pmc Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance
    Thomas R Fritsche
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 49:1468-76. 2005
    ....
  9. ncbi request reprint Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:187-93. 2005
    ..Further clinical studies should consider the role that tigecycline may play in the therapy for severe respiratory tract infections, both of nosocomial and community origin...
  10. ncbi request reprint Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004)
    Thomas R Fritsche
    JMI Laboratories, Inc, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:195-201. 2005
    ..Tigecycline represents a new choice among broad-spectrum parenteral agents for the common Gram-positive and -negative pathogens producing serious infections of skin and soft tissues...
  11. pmc Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin America
    Thomas R Fritsche
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:1843-5. 2008
    ..The global emergence of high-level aminoglycoside resistance has become a rapidly changing event requiring careful monitoring...
  12. ncbi request reprint Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:209-13. 2005
    ....
  13. doi request reprint Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006)
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 61:86-95. 2008
    ..These characteristics warrant continued evaluation of the agent as empiric therapy for cSSSIs, and in pneumonia, especially in those institutions/regions where MRSA and P. aeruginosa may be prevalent...
  14. ncbi request reprint Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006)
    T R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    J Chemother 20:170-4. 2008
    ..Penicillin-resistant strains were largely resistant to all tested ss-lactams. We confirm the continued spectrum and potency for cefditoren against S. pneumoniae that surpasses that of other orally administered cephalosporins...
  15. pmc Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms
    Thomas R Fritsche
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 44:2988-90. 2006
    ....
  16. ncbi request reprint Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America:
    Thomas R Fritsche
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 47:435-40. 2003
    ..These findings confirm that the newer cephalosporins (cefepime and ceftriaxone) among broad-spectrum beta-lactam agents have a spectrum of activity that remains comprehensive for the commonly isolated Gram-positive pathogens...
  17. ncbi request reprint Importance of understanding pharmacokinetic/pharmacodynamic principles in the emergence of resistances, including community-associated Staphylococcus aureus
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    J Drugs Dermatol 4:s4-8. 2005
    ....
  18. ncbi request reprint Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)
    T R Fritsche
    JMI Laboratories, North Liberty, IA, USA
    Clin Microbiol Infect 11:974-84. 2005
    ....
  19. doi request reprint In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 60:399-403. 2008
    ....
  20. ncbi request reprint Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)
    Gary J Moet
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:7-13. 2007
    ..48.0%) when compared with other regions. Continued surveillance of pathogen prevalence and antimicrobial resistance patterns should provide information that is important to improve empiric care particularly in the hospital environment...
  21. ncbi request reprint Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens
    Jennifer M Streit
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 53:307-10. 2005
    ..In summary, dalbavancin was very active against a wide spectrum of resistant Gram-positive isolates and demonstrated greater potency than vancomycin or teicoplanin...
  22. ncbi request reprint Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004)
    H S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Clin Microbiol Infect 12:844-52. 2006
    ..This novel lipopeptide (daptomycin) appears to be an excellent alternative therapeutic option for serious infections caused by multidrug-resistant gram-positive organisms isolated in Europe...
  23. doi request reprint Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007)
    Thomas R Fritsche
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 63:440-6. 2009
    ....
  24. ncbi request reprint Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program
    Lalitagauri M Deshpande
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:231-6. 2004
    ....
  25. pmc International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003)
    Shawn A Messer
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 44:1782-7. 2006
    ....
  26. ncbi request reprint Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol
    R N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    J Chemother 17:593-600. 2005
    ..This high volume international survey indicates potential therapeutic roles for dalbavancin against many troublesome resistant Gram-positive phenotypes...
  27. ncbi request reprint Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003
    H S Sader
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Chemother 17:477-83. 2005
    ..The results of this study showed that daptomycin continues to be very active against clinical isolates of Gram-positive cocci isolated in Europe and Latin America...
  28. ncbi request reprint Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program
    D M Johnson
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 47:373-6. 2003
    ..It is apparent from this investigation that many commonly prescribed empiric treatments remain viable therapeutic options for CARTI caused by these two Gram-negative respiratory tract pathogens...
  29. ncbi request reprint Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)
    Jennifer M Streit
    The JONES Group JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IW 52317, USA
    Int J Antimicrob Agents 24:111-8. 2004
    ..Cefepime and the carbapenems (imipenem or meropenem) for Gram-negative isolates and linezolid for Gram-positive isolates, provided the broadest spectrum of in vitro activity against contemporary ICU pathogens in North America...
  30. ncbi request reprint Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers
    H S Sader
    JMI Laboratories, North Liberty, Iowa, USA
    J Chemother 20:28-32. 2008
    ..Resistance rates to oxacillin and levofloxacin were generally elevated, especially when an intravenous catheter was the source of infection...
  31. ncbi request reprint Frequency of occurrence and daptomycin susceptibility rates of Gram-positive organisms causing bloodstream infections in cancer patients
    H S Sader
    JMI Laboratories, North Libtery, Iowa 52314, USA
    J Chemother 20:570-6. 2008
    ..These results indicate that daptomycin has an appropriate spectrum and potency to be used for empirical coverage of Gram-positive infections (especially BSI) in cancer patients in the hospitals surveyed in the USA...
  32. ncbi request reprint Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:203-8. 2005
    ..aeruginosa) isolated from ICU patients and may represent an excellent option for the treatment of infections in this clinical environment...
  33. ncbi request reprint Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:181-6. 2005
    ..Serious infections in nosocomial environments should benefit from tigecycline use among the investigational phase 3 agents focused toward resistant strains...
  34. ncbi request reprint Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program
    Thomas R Fritsche
    Jones Microbiology Institute Laboratories, North Liberty, IA 52317, USA
    Clin Infect Dis 41:S276-8. 2005
    ....
  35. ncbi request reprint Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003)
    Paul R Rhomberg
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:273-81. 2004
    ..and Acinetobacter baumannii isolates. Continued surveillance of the carbapenem class and other broad-spectrum agents is warranted to monitor activity against pathogens causing serious infections in hospitalized patients...
  36. ncbi request reprint Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004)
    P R Rhomberg
    JMI Laboratories, North Liberty, Iowa 52317, USA
    J Chemother 17:459-69. 2005
    ....
  37. ncbi request reprint Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Ant
    Jennifer M Streit
    JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 27:367-75. 2006
    ....
  38. ncbi request reprint Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004)
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, Iowa, USA
    Microb Drug Resist 12:223-30. 2006
    ....
  39. ncbi request reprint Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program
    Tamara R Anderegg
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 26:13-21. 2005
    ..63DDD/100 patient days (a 50% increase since 2002), and indicates the important role of hospital hygiene practice in preventing the dissemination of oxazolidinone resistances, should they be detected...
  40. ncbi request reprint Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests
    Ronald N Jones
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 56:1047-52. 2005
    ..To evaluate bactericidal activity of PPI-0903M and in vitro testing parameters for this compound...
  41. doi request reprint Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States
    Douglas J Biedenbach
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 61:240-4. 2008
    ..5 microg/mL), including beta-lactamase producers (MIC(50), 0.12 vs < or =0.008 microg/mL). Cefditoren retains potent activity against respiratory tract isolates in the United States, including those with resistance phenotypes...
  42. ncbi request reprint Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus
    Sudha Pottumarthy
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 53:225-31. 2005
    ....
  43. ncbi request reprint Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997-2003)
    Sudha Pottumarthy
    Jones Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 51:147-50. 2005
    ..3-79.1%). Our findings confirm that the parenteral cephalosporins, cefepime, and ceftriaxone possess significant activity against those MDR pneumococci responsible for an increasing number of serious respiratory tract infections...
  44. ncbi request reprint In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections
    Thomas R Fritsche
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:201-9. 2004
    ....
  45. ncbi request reprint Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)
    Paul R Rhomberg
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 56:57-62. 2006
    ....
  46. pmc Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 50:2330-6. 2006
    ....
  47. ncbi request reprint Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    Int J Infect Dis 13:291-5. 2009
    ..In the present study, we evaluated the antimicrobial susceptibility patterns of S. aureus causing BSI in dialysis patients compared to those causing BSI in other patient populations...
  48. ncbi request reprint Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)
    Ronald N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:109-16. 2007
    ..4% and 2.3%, respectively). Our results indicate that cefepime was the most broad-spectrum cephalosporin analyzed and remains a very potent alternative for the treatment of contemporary pediatric infections in North America...
  49. pmc Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:570-3. 2008
    ....
  50. ncbi request reprint Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 30:514-20. 2007
    ..1%) and imipenem in Spain (87.7%). Our results suggest that tigecycline represents a viable additional option for the empirical treatment of cSSSI in these countries...
  51. ncbi request reprint Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:341-4. 2007
    ....
  52. pmc Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:2171-5. 2009
    ..aureus [MRSA]), beta-hemolytic Streptococcus spp., and Enterococcus faecalis strains tested. In addition, iclaprim exhibited bactericidal activity against all S. aureus strains tested, including MRSA...
  53. ncbi request reprint Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:9-17. 2007
    ....
  54. ncbi request reprint Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 59:467-72. 2007
    ....
  55. pmc Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci
    Ronald N Jones
    JMI Laboratories, Inc, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 50:2583-6. 2006
    ..12 microg/ml for Staphylococcus aureus and < or = 0.03 microg/ml for Streptococcus pyogenes; no cross-resistance was observed for organism subsets resistant to oxacillin, erythromycin, or mupirocin...
  56. ncbi request reprint Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004)
    Amy A Watters
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 57:914-23. 2006
    ....
  57. ncbi request reprint Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels
    James E Ross
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 51:219-21. 2005
    ..0%) for on-scale results analyzed at +/-1 log2 dilution for same- and between-day comparisons. Newer and investigational fluoroquinolone agents, including gemifloxacin, can be tested with confidence using these dry-form MIC panels...
  58. ncbi request reprint Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:71-4. 2005
    ..016 mug/mL (with higher values for ertapenem). Doripenem appears to be a promising, potent carbapenem for parenteral use against contemporary Gram-negative bacilli producing various beta-lactamases...
  59. ncbi request reprint Initial results from a longitudinal international surveillance programme for anidulafungin (2003)
    Shawn A Messer
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 54:1051-6. 2004
    ..This longitudinal study evaluated the in vitro activity of anidulafungin against 880 clinical yeast isolates and 68 mould isolates from 64 medical centres in North America, Latin America and Europe...
  60. ncbi request reprint Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program
    James E Ross
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:53-8. 2005
    ..Rare linezolid-resistant strains were identified in the United States only (0.05% resistance overall)...
  61. ncbi request reprint Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents
    Sudha Pottumarthy
    The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 25:282-9. 2005
    ..4%). Local and global surveillance studies of common respiratory pathogens such as S. pneumoniae remain instrumental to guide clinicians in appropriate empirical treatments and to emphasize the need for prudent antimicrobial use...
  62. ncbi request reprint Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates
    Jennifer M Streit
    The JONES Group JMI Laboxratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 48:137-43. 2004
    ..Some VRE were inhibited by very low dalbavancin concentrations (< or = 1 microg/ml; Van B phenotypes). Further clinical development seems warranted for this once-weekly administered agent...
  63. ncbi request reprint Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 50:201-4. 2004
    ..Daptomycin showed a significant potency and spectrum against Gram-positive species, including multidrug-resistant strains, and may represent a reasonable therapeutic option for infections caused by these important pathogens...
  64. ncbi request reprint Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates
    Lalitagauri Deshpande
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 50:73-5. 2004
    ..BAL9141 displayed a predominant bactericidal activity against the majority of Gram-positive and -negative species, including resistant subsets, making it an attractive candidate for further development...
  65. ncbi request reprint Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:283-7. 2004
    ..Only 0.5% of all 415 recent CA-SSTI pathogens were resistant to cefdinir (MIC, > or = 4 mg/L). Cefdinir showed a spectrum and potency comparable or superior to other orally administered beta-lactams (cephalexin)...
  66. ncbi request reprint Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003)
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, Iowa, USA
    Diagn Microbiol Infect Dis 49:211-6. 2004
    ..09% of all PSA isolates). Meropenem remained the most active antimicrobial agent tested in the program, and surveillance networks must implement epidemiologic typing to accurately assess the role of clonal spread on the study results...
  67. ncbi request reprint Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates
    Ronald N Jones
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 53:804-7. 2004
    ..To evaluate the potency of a novel peptide deformylase inhibitor, NVP PDF-713, against Gram-positive organisms having resistances to linezolid or quinupristin/dalfopristin...
  68. pmc Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains
    Helio S Sader
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 49:3501-12. 2005
    ....
  69. ncbi request reprint Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations
    Ronald N Jones
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 57:279-87. 2006
    ..To investigate the activity of linezolid (an oxazolidinone), a potent choice for community- and hospital-acquired infections, via a worldwide surveillance network called the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program...
  70. pmc Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents
    Helio S Sader
    JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    J Clin Microbiol 44:1101-4. 2006
    ..aeruginosa that exhibit contemporary resistance mechanisms would be prudent to minimize the potential for serious reporting errors...
  71. ncbi request reprint Activity of gemifloxacin tested against Neisseria gonorrhoeae isolates including antimicrobial-resistant phenotypes
    Sudha Pottumarthy
    Jones Microbiology Institute Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 54:127-34. 2006
    ..Gemifloxacin should be considered for further development as a therapeutic option to treat uncomplicated infections due to emerging strains resistant to penicillins, tetracycline, and some older fluoroquinolones...
  72. ncbi request reprint Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 54:149-53. 2006
    ..Dalbavancin wild-type MIC distributions remain unchanged compared with prior sampled years (2002-2003) in the USA...
  73. pmc Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:1153-5. 2008
    ..All isolates had the Panton-Valentine leukocidin genes and staphylococcal cassette chromosome mec type IV, while 67.8% of isolates displayed pulsed-field gel electrophoresis clonal type USA300-0114...
  74. ncbi request reprint In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:27-32. 2007
    ....
  75. ncbi request reprint Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North Ameri
    Jeffrey T Kirby
    JMI Laboratories, Inc, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 56:75-82. 2006
    ..4%), and cited age-related variations in pathogen occurrence and/or susceptibility patterns by species must be considered for empiric regimes for hematology and oncology patients...
  76. doi request reprint In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 61:76-9. 2008
    ..The average -16% activity across all generic lots was equivalent to underdosing piperacillin/tazobactam by 2.6 g daily for serious clinical infections (4.5 g Q6 h)...
  77. pmc Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004)
    Lalitagauri M Deshpande
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 44:3775-7. 2006
    ..03 to 0.06 microg/ml). The BRO-2 incidence rates by year were 3 to 4% overall (96 to 97% for BRO-1) and were the highest in Canada (7.9%), with the incidence in the United States being only 2.0%...
  78. ncbi request reprint Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations
    Ronald N Jones
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Antimicrob Chemother 54:144-54. 2004
    ..To investigate the potency of doripenem, a broad-spectrum carbapenem characterized by a wider spectrum of activity combining antimicrobial and bactericidal features of imipenem and meropenem...
  79. ncbi request reprint Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002)
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 49:147-9. 2004
    ....
  80. ncbi request reprint Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004)
    Paul R Rhomberg
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 54:249-57. 2006
    ..Possible emergence of resistance mechanisms via clonal dissemination proves to be among the principle threats that compromise carbapenem therapy, where meropenem maintains the broadest spectrum of coverage...
  81. ncbi request reprint Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide
    Ronald N Jones
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 23:197-9. 2004
    ..9-92.2% of dalbavancin MIC comparisons. These dalbavancin MIC results demonstrated the acceptable accuracy of commercially-prepared broth microdilution products for use in subsequent clinical trials...
  82. ncbi request reprint Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:1-7. 2007
    ..pneumoniae that have created therapeutic dilemmas for all RTI presentations. Garenoxacin appears to be a welcome addition to the CAP treatment options, particularly for the emerging MDR pneumococci strains...
  83. ncbi request reprint Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002)
    Helio S Sader
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 47:515-25. 2003
    ..These rates of increased susceptibility could sustain and enhance the clinical activity of orally administered beta-lactams such as cefdinir...
  84. ncbi request reprint Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 57:5S-12S. 2007
    ....
  85. ncbi request reprint Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 53:329-32. 2005
    ..Resistance to oxacillin or vancomycin did not influence daptomycin activity against S. aureus or E. faecalis...
  86. ncbi request reprint Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:265-73. 2005
    ..Continued resistance surveillance is critical to monitor the effectiveness of widely used parenteral antimicrobial agents such as cefepime...
  87. ncbi request reprint Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study
    James E Ross
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 29:295-301. 2007
    ..With MDR in Gram-positive organisms increasing in prevalence, continued surveillance of linezolid appears to be prudent practice as linezolid becomes more widely prescribed for these difficult-to-treat infections...
  88. ncbi request reprint Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae
    Ronald N Jones
    The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 52:129-33. 2005
    ..Parenteral cephalosporins (cefepime or ceftriaxone) continue to be potent and safe for use in hospitalized patients with S. pneumoniae community-acquired pneumonia, used with or without co-drugs according to published guidelines...
  89. ncbi request reprint Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program
    Lalitagauri M Deshpande
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 58:163-70. 2007
    ..faecium. Clonal spread appears to be a dominant factor of MDR VRE dissemination on both continents, and further monitoring is critical to assist in the control of these resistant pathogens...
  90. ncbi request reprint Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004)
    Lalitagauri M Deshpande
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 28:578-81. 2006
    ....
  91. pmc Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program
    Ronald N Jones
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 44:2622-5. 2006
    ..Vancomycin test results most reliably predict dalbavancin susceptibility until validated commercial reagents become available for direct testing in clinical practice...
  92. ncbi request reprint Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis)
    Ronald N Jones
    The JONES Group, JMI Laboratories Inc, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 51:139-41. 2005
    ..meningitidis and N. gonorrhoeae, respectively. All comparison agents were more active than this peptide deformylase inhibitor against this genus...
  93. ncbi request reprint Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004)
    Douglas J Biedenbach
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 30:143-9. 2007
    ..Daptomycin was demonstrated to have excellent in vitro activity when tested against Gram-positive isolates collected from Asia-Pacific countries, including hVISA strains...
  94. ncbi request reprint LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 59:309-17. 2007
    ..Overall, 99.55% of the tested 2006 LEADER program isolates remained susceptible to linezolid at current Clinical and Laboratory Standards Institute breakpoints...
  95. pmc Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
    Douglas J Biedenbach
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 45:998-1004. 2007
    ..Dalbavancin demonstrated excellent potency and activity (100% susceptibility at proposed breakpoints) against common causes of SSSI pathogens in this U.S. multicenter study sample...
  96. ncbi request reprint Enhancement of in vitro cytopathogenicity by Acanthamoeba spp. following acquisition of bacterial endosymbionts
    T R Fritsche
    Department of Laboratory Medicine, University of Washington School of Medicine, Seattle 98195 7110, USA
    FEMS Microbiol Lett 166:231-6. 1998
    ..This report provides evidence that obligate bacterial endosymbionts are able to enhance amoebic pathogenic potential in vitro by some as-yet unknown mechanism...
  97. pmc Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile
    A P Limaye
    Department of Laboratory Medicine, University of Washington, Seattle, Washington 98195, USA
    J Clin Microbiol 38:1696-7. 2000
    ..We report a case of severe pseudomembranous colitis due to a toxin A(-) B(+) strain of Clostridium difficile in an immunosuppressed patient and discuss the implications for diagnostic testing in suspected C. difficile-associated diarrhea...
  98. ncbi request reprint Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine
    Robertino Mera
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Microb Drug Resist 14:101-7. 2008
    ..S. pediatric population in 2005. Changes over time in serogroup prevalence and multidrug-resistance (MR) to antimicrobials were evaluated using the U.S. SENTRY surveillance program...
  99. ncbi request reprint Emerging epidemic of metallo-beta-lactamase-mediated resistances
    Ronald N Jones
    Diagn Microbiol Infect Dis 51:77-84. 2005
  100. ncbi request reprint Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)
    Michael A Pfaller
    Department of Pathology and Epidemiology, University of Iowa College of Medicine and College of Public Health, Iowa City, IA 52242, USA
    Diagn Microbiol Infect Dis 56:63-8. 2006
    ..isolated in North American medical centers. Continued resistances surveillance monitoring will be necessary to assess the effectiveness of widely used broad-spectrum antimicrobials as novel resistance mechanisms emerge...
  101. ncbi request reprint Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections
    Beth P Goldstein
    Vicuron Pharmaceuticals, King of Prussia, PA, USA
    Diagn Microbiol Infect Dis 54:83-7. 2006
    ..25 microg/mL) and achieved significant (P < 0.05) clinical success when compared with vancomycin...